絞り込み

16758

広告

「elotuzumab」の検索結果

265件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

[Successful treatment with a combination of elotuzumab, lenalidomide and dexamethasone of extramedullary disease in a patient with refractory multiple myeloma].

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real life studies and meta-analyses.

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.

Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

[The role of fibrocytes in myelofibrosis and fibrocyte regulation as a novel treatment approach].

Critical Role of Lipid Scramblase TMEM16F in Phosphatidylserine Exposure and Repair of Plasma Membrane after Pore Formation.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.

[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation].

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります